Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.58 |
| ▸ | MEN1 | O00255 | 6/20 | 0.58 |
| ▸ | HTT | P42858 | 4/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.48 |
| ▸ | HPN | P05981 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | CA4 | P22748 | 1/20 | 0.45 |
| ▸ | CA5A | P35218 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | PDE4A | P27815 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1463494 | 0.91 | KMT2A (0.55) | KMT2AMEN1HTTMAPTLMNA | |
| SCHEMBL1463507 | 0.89 | KMT2A (0.45) | KMT2AMEN1HTTMAPTLMNA | |
| SCHEMBL1463337 | 0.88 | KDR (0.54) | KMT2AMEN1HTTMAPTLMNA | |
| SCHEMBL1463395 | 0.87 | KMT2A (0.45) | KMT2AMEN1HTTMAPTLMNA | |
| SCHEMBL1463359 | 0.86 | KMT2A (0.58) | KMT2AMEN1HTTMAPTLMNA | |
| SCHEMBL4019017 | 0.86 | S1PR2 (0.47) | KMT2AMEN1HTTMAPTLMNA | |
| SCHEMBL1463540 | 0.85 | GRIK1 (0.50) | KMT2AMEN1HTTMAPTLMNA | |
| SCHEMBL1463473 | 0.84 | KMT2A (0.46) | KMT2AMEN1MAPTLMNACA2 | |
| SCHEMBL1464054 | 0.84 | KMT2A (0.51) | KMT2AMEN1HTTMAPTLMNA | |
| SCHEMBL5468334 | 0.84 | MAPT (0.46) | KMT2AMEN1HTTMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210251963-A1 | UREA DERIVATIVES FOR USE IN THE TREATMENT OF SUBJECTS WITH ELEVATED EXPRESSION AND/OR ACTIVITY OF SRPK1 | SCANDION ONCOLOGY A/S (DK) | 2021-08-19 | — | — | US | claimed |
| EP-1663192-B1 | hERG1 CHANNEL OPENERS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS | NEUROSEARCH AS (DK) | 2008-12-03 | — | — | EP | claimed |
| US-20070293553-A1 | Diphenylurea Derivatives Useful As Potassium Channel Activators | NEUROSEARCH A/S (DK) | 2007-12-20 | — | — | US | claimed |
| US-20060281794-A1 | Erg channel openers for the treatment of cardiac arrhythmias | NEUROSEARCH A/S (DK) | 2006-12-14 | — | — | US | claimed |
| EP-1663192-A1 | ERG CHANNEL OPENERS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS | Poseidon Pharmaceuticals A/S (DK) | 2006-06-07 | — | — | EP | claimed |
| WO-2005023238-A1 | ERG CHANNEL OPENERS FOR THE TREATMENT OF HYPEREXCITABILITY-RELATED NEURONAL DISEASES | POSEIDON PHARMACEUTICALS A/S (DK) | 2005-03-17 | — | — | WO | claimed |
| WO-2005023237-A1 | ERG CHANNEL OPENERS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS | POSEIDON PHARMACEUTICALS A/S (DK) | 2005-03-17 | — | — | WO | claimed |
| US-20210251963-A1 | UREA DERIVATIVES FOR USE IN THE TREATMENT OF SUBJECTS WITH ELEVATED EXPRESSION AND/OR ACTIVITY OF SRPK1 | SCANDION ONCOLOGY A/S (DK) | 2021-08-19 | — | — | US | disclosed |
| US-20110071164-A1 | ERG CHANNEL OPENERS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS | OLESEN SOEREN PETER | 2011-03-24 | — | — | US | disclosed |
| US-7851492-B2 | ERG channel openers for the treatment of cardiac arrhythmias | NEUROSEARCH A/S (DK) | 2010-12-14 | — | — | US | disclosed |
| EP-1663192-B1 | hERG1 CHANNEL OPENERS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS | NEUROSEARCH AS (DK) | 2008-12-03 | — | — | EP | disclosed |
| US-20070293553-A1 | Diphenylurea Derivatives Useful As Potassium Channel Activators | NEUROSEARCH A/S (DK) | 2007-12-20 | — | — | US | disclosed |
| US-20060281794-A1 | Erg channel openers for the treatment of cardiac arrhythmias | NEUROSEARCH A/S (DK) | 2006-12-14 | — | — | US | disclosed |
| EP-1663192-A1 | ERG CHANNEL OPENERS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS | Poseidon Pharmaceuticals A/S (DK) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005023237-A1 | ERG CHANNEL OPENERS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS | POSEIDON PHARMACEUTICALS A/S (DK) | 2005-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281794-A1 | Erg channel openers for the treatment of cardiac arrhythmias | KCNJ2, KCNN3, KCNE1 | KMT2A 2189/4885MEN1 2084/4885HTT 1742/4885 |
| US-20070293553-A1 | Diphenylurea Derivatives Useful As Potassium Channel Activators | KCNJ2, KCNH2, KCNH3 | KMT2A 603/4885MEN1 3855/4885HTT 1128/4885 |
| US-20110071164-A1 | ERG CHANNEL OPENERS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS | KCNJ2, KCNN3, KCNE1 | KMT2A 2189/4885MEN1 2084/4885HTT 1742/4885 |
| US-20210251963-A1 | UREA DERIVATIVES FOR USE IN THE TREATMENT OF SUBJECTS WITH ELEVATED EXPRESSION AND/OR ACTIVITY OF SRPK1 | SRPK1, SRPK3, HNRNPK | KMT2A 4081/4885MEN1 4759/4885HTT 1836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.